Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Boehringer's Idiopathic Pulmonary Fibrosis Drug Gets Breakthrough Designation | Contract Pharma

What are you searching for?

Sign in
Breaking News, Trials & Filings

Boehringer’s Idiopathic Pulmonary Fibrosis Drug Gets Breakthrough Designation

Oral, phosphodiesterase 4B (PDE4B) inhibitor has potential to address both pulmonary fibrosis scarring and inflammation.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Boehringer Ingelheim’s investigational therapy, BI 1015550, for the treatment of idiopathic pulmonary fibrosis (IPF) was granted Breakthrough Therapy Designation by the FDA. BI 1015550 is an oral, phosphodiesterase 4B (PDE4B) inhibitor with the potential to address both pulmonary fibrosis – an irreversible scarring of lung tissue that negatively impacts lung function – and inflammation associated with progressive fibrosing interstitial lung diseases (ILDs).
 
The efficacy, safety, and tolerability of BI 1015550 was studied in a Phase II randomized, double-blind, placebo-controlled trial of patients with IPF (n=147). The primary endpoint was change from baseline in Forced Vital Capacity (FVC) – a measure of lung function – over a 12-week treatment period. 
 
The FDA Breakthrough Therapy designation is supported by data collected to date. Initiation of the Phase III program is expected later this year.
 
The FDA established the Breakthrough Therapy Designation process to expedite the development and review of drugs for serious or life-threatening conditions where preliminary clinical evidence indicate that the therapy may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics